Brightline-2: A Phase IIa/IIb, Open-label, Single-arm, Multi-centre Trial of Brigimadlin (BI 907828) for Treatment of Patients With Locally Advanced / Metastatic, MDM2 Amplified, TP53 Wild-type Biliary Tract Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, or Other Selected Solid Tumours

MC #1-JIT-1403-0011 (Brightline-2)

NCT #
Condition(s)
Bile Duct Cancer (Cholangiocarcinoma), Lung Cancer (NSCLC), Pancreatic Cancer, Urothelial Cancer
Molecular Target(s)
MDM2
Drug Classification(s)
Molecular Targeted Therapy
Agents(s)
Zenocutuzumab, a Full Length IgG1 Bispecific Antibody Targeting HER2 and HER3
Phase(s)
II

Mechanism of Action

BI 907828 is a so-called MDM2 inhibitor

Purpose

Location

Mary Crowley Cancer Research - Medical City Dallas

Connect With Us

Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.

7777 Forest Lane,
Building C-707
Dallas, TX 75230

972.566.3000